FTC sues drug middlemen for allegedly inflating insulin prices
FTC sues drug middlemen for allegedly inflating insulin prices
www.cnbc.com FTC sues drug middlemen for allegedly inflating insulin prices
The FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts.
- The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while "artificially" inflating costs for patients.
- The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts, and their affiliated group purchasing organizations.
- The FTC may also recommend suing insulin manufacturers Eli Lilly, Sanofi and Novo Nordisk in the future.